$Bevacizumab in Association With de Gramont 5-Fluorouracil/Folinic Acid in Patients With Oxaliplatin-, Irinotecan-, and Cetuximab-Refractory Colorectal Cancer: A Single-Center Phase 2 Trial$

Bevacizumab in Association With de Gramont 5-Fluorouracil/Folinic Acid in Patients With Oxaliplatin-, Irinotecan-, and Cetuximab-Refractory Colorectal Cancer: A Single-Center Phase 2 Trial

The aim of the current study was the investigation of the value of bevacizumab+5-fluorouracil(5-FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. The authors included 48 heavily pretreated patients (colon:rectum, 33:15; men:women, 23:25;...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2009-10, Vol.115 (20), p.4849-4856
Hauptverfasser:	VINCENZI, Bruno, SANTINI, Daniele, COPPOLA, Roberto, TONINI, Giuseppe, RUSSO, Antonio, SPOTO, Chiara, VENDITTI, Olga, GASPARRO, Simona, RIZZO, Sergio, BEOMONTE ZOBEL, Bruno, CARICATO, Marco, VALERI, Sergio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Cetuximab Colorectal Neoplasms - drug therapy Drug Administration Schedule Drug Resistance, Neoplasm Female Fluorouracil - administration & dosage Gastroenterology. Liver. Pancreas. Abdomen Humans Leucovorin - administration & dosage Male Medical sciences Middle Aged Retreatment Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!